Table 1 Baseline patients’ characteristics in the two cohorts (Lenvatinib and Atezolizumab plus Bevacizumanb).
Lenvatinib (n = 430) | Atezolizumab plus bevacizumab (n = 300) | P | |
|---|---|---|---|
Sex | |||
Male | 358 (83) | 233 (78) | 0.068537 |
Female | 72 (17) | 67 (22) | |
Viral | |||
Y | 249 (58) | 157 (52.5) | 0.129097 |
N | 178 (41) | 142 (47) | |
Na | 3 (1) | 1 (0.5) | |
Nash | |||
Y | 121 (28) | 69 (23) | 0.122745 |
N | 305 (70.5) | 229 (76) | |
Na | 4 (1.5) | 2 (1) | |
Diabetes | |||
Y | 182 (42.5) | 105 (35) | 0.045443 |
N | 246 (57) | 194 (64.5) | |
Na | 2 (0.5) | 1 (0.5) | |
Metformin | |||
Y | 65 (15) | 50 (16.5) | 0.606169 |
N | 363 (84.5) | 249 (83) | |
Na | 2 (0.5) | 1 (0.5) | |
Statin | |||
Y | 37 (8.5) | 41 (13.5) | 1.000000 |
N | 227 (53) | 258 (86) | |
Na | 166 (38.5) | 1 (0.5) | |
Aspirin | |||
Y | 47 (11) | 45 (15) | 0.425474 |
N | 219 (51) | 254 (84.5) | |
Na | 164 (38) | 1 (0.5) | |
Insulin | |||
Y | 29 (7) | 32 (10.5) | 1.000000 |
N | 237 (55) | 267 (89) | |
Na | 164 (38) | 1 (0.5) | |
Child | |||
A | 387 (90) | 266 (88.5) | 0.274485 |
B | 31 (7) | 29 (9.5) | |
Na | 12 (3) | 5 (2) | |
BCLC | |||
B | 193 (45) | 115 (38) | 0.047178 |
C | 227 (53) | 184 (61.5) | |
Na | 10 (2) | 1 (0.5) | |
ECOG | |||
0 | 328 (76.5) | 221 (73.5) | 0.482295 |
> 0 | 100 (23) | 77 (25.5) | |
Na | 2 (0.5) | 2 (1) | |
PVT | |||
Y | 66 (15.5) | 80 (26.5) | 0.000050 |
N | 319 (74) | 177 (59) | |
Na | 45 (10.5) | 43 (14.5) | |
AFP | |||
> 400 | 117 (27.5) | 93 (31) | 0.241967 |
≤ 400 | 303 (70.5) | 197 (65.5) | |
Na | 10 (2) | 10 (3.5) | |
NLR | |||
≥ 3 | 102 (24) | 43 (14) | 0.035902 |
< 3 | 249 (58) | 163 (54.5) | |
Na | 79 (18) | 94 (31.5) | |
Albumin | |||
≤ 3.5 | 139 (32) | 83 (27.5) | 0.187623 |
> 3.5 | 276 (64.5) | 208 (69.5) | |
Na | 15 (3.5) | 9 (3) | |
Bilirubin | |||
> 2 | 38 (9) | 19 (6) | 0.208849 |
≤ 2 | 374 (87) | 274 (91.5) | |
Na | 18 (4) | 7 (2.5) | |
EHD | |||
Y | 164 (38) | 102 (34) | 0.274458 |
N | 265 (61.5) | 196 (65) | |
Na | 1 (0.5) | 2 (1) | |
